Stryker is a medical technology company that provides the implants and surgical tools hospitals use for joint replacements and trauma surgeries. The business reached $25.12 billion in revenue in 2025, representing 11% growth over the prior year. It is currently the dominant player in robotic-assisted surgery for knees and hips, a position that cements its role in the modern operating room.
The investment thesis on Stryker is that its Mako robotic platform creates a high-margin razor-and-blade model that competitors cannot easily displace once a hospital has committed to the system. Stryker sells the expensive robot upfront, but the real value is the locked-in stream of proprietary implants that must be used with it. If robotic adoption continues to climb while hospital procedure volumes stay high, earnings will compound.
We think Stryker is a rare large-cap compounder that has successfully turned a hardware product into a recurring revenue engine through its robotic ecosystem. The main risk is a sudden shift in hospital capital budgets that could slow the sale of new robotic systems.
Stryker’s stock has stayed mostly flat for years and recently dropped. While the company is the leader in robotic surgery tools and keeps growing, its share price has fallen about 15% over the past year. Even though they are buying new technology and selling more equipment to hospitals, investors have grown cautious lately.
What does it do?
Stryker is a mature business that earns money by selling specialized medical equipment and the disposable implants used in surgeries. When a surgeon performs a hip or knee replacement, they use Stryker's metal and plastic implants. The company also sells the Mako robotic system, which helps surgeons place those implants with higher precision. Beyond orthopaedics, the company provides a wide range of surgical tools, hospital beds, and emergency transport equipment. Customers pay upfront for the large equipment and then buy the high-margin implants and accessories on a recurring basis as surgeries are performed.
Where does revenue come from?
Stryker generates the majority of its sales from its MedSurg and Neurotechnology divisions, followed closely by Orthopaedics. The MedSurg segment includes power tools, endoscopy systems, and hospital infrastructure like beds. Orthopaedics focuses on joint replacements and trauma implants. Neurotechnology covers products for brain and spine surgeries. About 74% of revenue comes from the United States, with the remainder spread across international markets including Europe and Asia.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Stryker serves thousands of hospitals, surgical centers, and emergency medical services providers globally. The business does not sell directly to patients but rather to the institutions where surgeons perform their work. In the most recent fiscal year, the company grew revenue to $25.12 billion, supported by high demand for joint procedures as the global population ages. Management notes that the Mako robotic system is now a primary driver of customer loyalty, as hospitals that invest in the million-dollar robot are highly likely to buy all their compatible implants from Stryker. While specific hospital counts are not always disclosed in quarterly reports, the company operates in over 75 countries and maintains a leading position in the $50 billion global medical device market.
What gives it staying power?
Stryker has staying power because of the high switching costs and surgeon training required to use its specialized systems. Once a surgeon is trained on the Mako robotic platform and a hospital has integrated Stryker's software, switching to a competitor's system requires significant time, retraining, and capital expense.
Where is it headed?
Stryker is headed toward a future where robotics and digital data are integrated into every stage of the surgical process. The company is expanding the Mako platform into spine and shoulder surgeries to replicate the success it had in knees and hips. This strategic bet aims to turn Stryker from a hardware supplier into a digital surgery partner for hospitals.
The business is accelerating, with 2025 revenue reaching $25.12 billion and growing 11% compared to the prior year. This growth is driven by both high procedure volumes and the continued rollout of the Mako robotic platform. Stryker has maintained a consistent pattern of high-single-digit to low-double-digit revenue growth over the last several years.
Cash generation is high and tracks earnings closely, with free cash flow of $4.28 billion in 2025. This indicates that the company's profits are real and not just accounting entries. Stryker reinvests a significant portion of this cash into research and development to maintain its lead in surgical robotics while returning the rest through dividends and acquisitions.
Stryker carries a manageable debt-to-equity ratio of 0.66x, providing plenty of room to fund future acquisitions. The company has used its balance sheet effectively to buy smaller medical technology firms that tuck into its existing sales channels. This level of leverage is conservative for a business with such predictable and recurring cash flows.
Stryker is a financially strong compounder that has successfully translated its leadership in robotics into consistent revenue and cash flow growth.
The Mako robotic platform is driving a 63.7% gross margin by pulling through high-margin joint implants. This razor-and-blade model ensures that every robot sold creates a multi-year stream of profitable sales. The company's scale allows it to maintain these margins even as it expands into new international markets.
The primary risk is a slowdown in hospital capital spending which could delay the purchase of expensive robotic systems. If hospitals face budget constraints, they may wait longer to upgrade their surgical suites, which would slow Stryker's long-term market share gains. Management has navigated this in the past by offering flexible financing and leasing options for their equipment.
The medical device market for orthopaedics and surgical tools is roughly $50 billion today and is on track to exceed $65 billion by 2028. This is a highly attractive industry because aging global demographics create a steady, predictable rise in the demand for joint replacements. Pricing power is high because surgeons prefer familiar, high-quality tools where the cost of the device is small compared to the total cost of a surgery. Stryker is a dominant leader in this market, using its scale to outspend smaller rivals on research and robotic technology.
Competition in medical devices is based on clinical outcomes and surgeon preference rather than just price. Hospitals rarely switch providers once a surgical team has been trained on a specific system. This creates a rational market where established leaders like Stryker can maintain high margins despite intense competition from other large players.
Zimmer Biomet is the most direct threat in joints, but they have struggled to match Stryker's early lead in robotic-assisted surgery. Johnson & Johnson has significant resources through DePuy Synthes but is currently in a multi-year process of refreshing its product lineup to compete with Stryker's Mako. The most dangerous threat is Medtronic, which has a massive global footprint and is aggressively pushing its own robotic platforms into the spine and neurosurgery segments where Stryker is also expanding.
Stryker is clearly holding its ground and likely gaining share in the high-growth robotic surgery segment. Its consistent 11% revenue growth outpaces the broader industry average.
Stryker's primary protection comes from high switching costs and intangible assets in the form of its Mako robotic software. Surgeons spend years learning the nuances of a specific robotic system, making them extremely reluctant to switch to a competitor's platform. This loyalty ensures that once a Stryker robot is in an operating room, Stryker implants are used for almost every procedure.
The company's 63.7% gross margin and 15.1% return on equity prove that this is a high-quality business with real staying power. These numbers show that Stryker is not just competing on price but is being paid a premium for its technology and integration.
The moat is strengthening as Stryker expands its robotic platform into spine and shoulder procedures. The more types of surgery a hospital can perform on a single Stryker platform, the harder it becomes for that hospital to ever leave.
Consistently delivered 11% revenue growth and met earnings targets in 2025.
Generated $4.28B in free cash flow used for strategic acquisitions and dividends.
CEO Kevin Lobo has led the company for over a decade with substantial stock-based incentives.
Capital Allocation Track Record
Kevin Lobo has proven to be an exceptional leader who has successfully transformed Stryker into a technology-driven medical giant. Under his tenure, the company made the bold decision to acquire Mako Surgical, which at the time was a risky bet on robotics that has since become the company's crown jewel. Management has shown a consistent ability to identify small, high-growth medical technology firms and integrate them into Stryker's massive sales machine without overpaying or disrupting the core business.
The leadership-continuity risk is low as Stryker has a deep bench of experienced executives across its MedSurg and Orthopaedics divisions. While Kevin Lobo is central to the company's culture and strategy, the business operates on a decentralized model where individual segment presidents have significant autonomy. There is no dual-class control or major board independence concern, and the company has a long history of clear communication with its shareholders.
We expect revenue to grow from $27.3B in FY2026 to $39.8B in FY2031 (~8% CAGR), with EPS growing from $14.98 to $25.36 (~11% CAGR). The Mako robotic surgery platform creates a recurring stream of high-volume implant sales as more hospitals adopt the technology for joint replacements. Increased production volume allows the company to spread fixed factory costs across more units while high-margin replacement parts become a larger portion of the mix. EPS grows faster than revenue because profit margins are widening and the company is consistently buying back its own shares. Operating margin expected to reach ~24% by FY2031.
Mako robotics platform expands into spine and shoulder surgeries. If Mako becomes the standard for all orthopedic surgery, Stryker will dominate the highest-margin segments of the market.
International adoption of robotic surgery accelerates in Europe and Asia. Expanding the Mako footprint outside the U.S. opens a massive and largely untapped market for robotic implants.
Digital surgery software creates new recurring subscription revenue lines. Software that assists in pre-operative planning and post-operative monitoring could add high-margin recurring revenue.
Hospital budget cuts reduce the demand for expensive robotic systems. A downturn in hospital capital spending would slow the growth of the Mako installed base and future implant sales.
Competitors launch cheaper or more capable robotic surgery platforms. If Zimmer Biomet or Medtronic release a superior robot, Stryker could lose its lead in the robotic ecosystem.
Large-scale M&A deals fail to integrate or overvalue targets. Stryker relies on acquisitions for growth, and a single bad multi-billion dollar deal could damage its capital position.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach based on FY+1 earnings to derive our fair value. This framework fits Stryker because the company is a mature, GAAP-profitable healthcare leader with highly predictable procedure-driven revenue, making earnings the most reliable signal of long-term value compared to volatile revenue or cash flow metrics during M&A cycles.
Next year’s (FY2027) EPS of $16.73 multiplied by a 28x multiple gives a per-share fair value of $468. Our 28x multiple sits at the premium end of the peer range (Boston Scientific at 30x, Medtronic at 18x, Zimmer Biomet at 15x), which is justified by Stryker’s dominant market share in surgical robotics and its shift toward a high-margin software-as-a-service model. The $16.73 EPS basis is taken directly from the deterministic projection engine for FY2027, reflecting the first full year of normalized operations following the cyberattack and the Inari Medical integration.
Cross-checked with a 5-year Discounted Cash Flow (DCF), we arrive at a fair value of $471—within 1% of our Forward P/E result of $468, confirming the valuation's rigor. We used the deterministic engine's 10% discount rate and 3% terminal growth assumption, which accounts for the company's steady cash flow generation even during the recent digital disruption. This parity between the multiple-based approach and the cash-flow approach suggests the market is currently mispricing Stryker's long-term compounding ability due to short-term sentiment around the cyberattack.
We are assuming that Stryker successfully navigates the "catch-up" period for surgeries delayed during the March 2026 cyberattack. Historically, medical device leaders recover 85-90% of postponed procedure volume within two quarters of a disruption, and Stryker’s "SmartHospital" vision relies on these recurring procedure-based revenues returning to their 8-9% organic growth baseline by FY2027.
We assume the integration of Inari Medical will drive a 100-basis-point expansion in adjusted operating margins. The high-margin nature of vascular clot treatment tools matches Stryker’s existing "Growth Flywheel" M&A strategy, and management’s track record of successful integration suggests the targeted 27.2% to 28.2% margin expansion is achievable.
We are assuming the Mako SmartRobotics platform remains the "gold standard" with an installed base exceeding 3,500 units by the end of 2027. Mako is the primary driver of Stryker’s "Wide" moat; as the system expands into spine and shoulder applications, it creates a self-reinforcing loop where the growing installed base of hardware locks hospitals into high-margin implant consumption for years.
The single biggest risk is a permanent erosion of customer trust and data security reputation following the March 2026 cybersecurity breach. If hospital systems delay Mako installations or SmartHospital software rollouts due to security concerns, the forward multiple would likely compress from 28x to 20x, knocking roughly $134 off the per-share fair value. Watch for any reported "re-infections" or delays in the "restoration process" updates scheduled for the second half of 2026.
Bear case ($360): Mako SmartRobotics adoption in the Ambulatory Surgery Center (ASC) setting slows below 5% annual growth; or Cyberattack-related litigation or regulatory fines exceed $1.5B in one-time costs.
Bull case ($520): Inari Medical integration achieves 2026 margin targets six months ahead of schedule; or SmartHospital software licensing reaches 15% of MedSurg revenue by FY2028.
Clearthesis wrote this report from 40 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because the Mako robotic platform forces hospitals into a long-term cycle of high-margin recurring sales. Once a facility buys the robot, they are locked into using Stryker’s specific implants for every knee and hip replacement. This creates a persistent stream of income that is difficult for rivals to displace.
Skeptics think that Stryker’s aggressive pace of acquisitions could eventually outstrip its ability to integrate new technology effectively. Buying companies like Amplitude Vascular Systems to expand into coronary technology creates complexity and management risk that may hide underlying problems in the core orthopedic business.